Celcuity LLC
Yahoo Finance • last year
Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference
MINNEAPOLIS, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the 6th Annual Evercore ISI... Full story
Yahoo Finance • last year
Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
Received FDA clearance of IND to evaluate gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer (mCRPC) Entered into a clinical trial collaboration and supply agreement with Bayer AG... Full story
Yahoo Finance • last year
Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for t... Full story
Yahoo Finance • last year
Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences
MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chairman, Chief Executive O... Full story
Yahoo Finance • last year
Celcuity to Host Virtual Science Day for Investors
Leading key opinion leaders to review the treatment landscape in breast and prostate cancer and the importance of targeting the PI3K/mTOR pathway in hormonally driven tumor types Discussion of the planned Phase 1b/2 trial for gedatolisib i... Full story
Yahoo Finance • last year
Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial
MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into a clinical trial collab... Full story
Yahoo Finance • last year
Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer
- Received FDA clearance of IND for gedatolisib in combination with darolutamide - Virtual Science Day to be held on September 21, 2023 from 10:00 a.m. – 12:00 p.m. ET MINNEAPOLIS, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasda... Full story
Yahoo Finance • 2 years ago
Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
High response rates and encouraging median progression free survival rates were observed in patients regardless of PIK3CA mutation status Median progression free survival (PFS) of 42.3 months was reported for patients who were treatment n... Full story
Yahoo Finance • 2 years ago
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancer Entered into agreements for the private placement sale of $100 million of equity and to increase available debt facility from $25 milli... Full story
